Evaluación del tratamiento de linfoma de Hodgkin con esquema ABVD en Chile

Background: Hodgkin lymphoma has a high rate of curability, even in advanced stages. Aim: To assess the results of Hodgkin lymphoma treatment using the ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy regimen. Material and Methods: Analysis of a database held by the Chilean Mi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Cabrera C.,María Elena, Puga L.,Bárbara, Torres,Vivianne, Salinas,Mauricio
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2019
Materias:	Drug Therapy Hodgkin Disease Stem Cell Transplantation Survival
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872019000400437
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872019000400437
record_format	dspace
spelling	oai:scielo:S0034-988720190004004372019-08-14Evaluación del tratamiento de linfoma de Hodgkin con esquema ABVD en ChileCabrera C.,María ElenaPuga L.,BárbaraTorres,VivianneSalinas,Mauricio Drug Therapy Hodgkin Disease Stem Cell Transplantation Survival Background: Hodgkin lymphoma has a high rate of curability, even in advanced stages. Aim: To assess the results of Hodgkin lymphoma treatment using the ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy regimen. Material and Methods: Analysis of a database held by the Chilean Ministry of Health, including all patients treated at accredited cancer treatment centers. Results: Data for 915 patients, median age 35 years (range 15-86 years) and followed for a median of 97 months (range 1-347 months) were analyzed. Forty-one percent had localized disease. Overall survival at five years for localized and advanced stages was 92% and 74%, respectively. The figures for progression free survival were 87% and 64%, respectively. Patients with relapse who received autologous stem cell transplantation (ASCT) had a five year overall survival of 92%, compared to 64% among those who did not undergo this procedure (p < 0.01). The Guarantees in Health Program set up by the Ministry of Health, was associated with earlier stage disease at diagnosis. Conclusions: The ABVD regimen achieves high rates of cure in localized stages of the disease but the results in advanced stages are not optimal. ASCT significantly improves survival in patients with relapse. The Guarantees in Health Program is associated with earlier diagnosis of the disease.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.147 n.4 20192019-04-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872019000400437es10.4067/S0034-98872019000400437
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Drug Therapy Hodgkin Disease Stem Cell Transplantation Survival
spellingShingle	Drug Therapy Hodgkin Disease Stem Cell Transplantation Survival Cabrera C.,María Elena Puga L.,Bárbara Torres,Vivianne Salinas,Mauricio Evaluación del tratamiento de linfoma de Hodgkin con esquema ABVD en Chile
description	Background: Hodgkin lymphoma has a high rate of curability, even in advanced stages. Aim: To assess the results of Hodgkin lymphoma treatment using the ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy regimen. Material and Methods: Analysis of a database held by the Chilean Ministry of Health, including all patients treated at accredited cancer treatment centers. Results: Data for 915 patients, median age 35 years (range 15-86 years) and followed for a median of 97 months (range 1-347 months) were analyzed. Forty-one percent had localized disease. Overall survival at five years for localized and advanced stages was 92% and 74%, respectively. The figures for progression free survival were 87% and 64%, respectively. Patients with relapse who received autologous stem cell transplantation (ASCT) had a five year overall survival of 92%, compared to 64% among those who did not undergo this procedure (p < 0.01). The Guarantees in Health Program set up by the Ministry of Health, was associated with earlier stage disease at diagnosis. Conclusions: The ABVD regimen achieves high rates of cure in localized stages of the disease but the results in advanced stages are not optimal. ASCT significantly improves survival in patients with relapse. The Guarantees in Health Program is associated with earlier diagnosis of the disease.
author	Cabrera C.,María Elena Puga L.,Bárbara Torres,Vivianne Salinas,Mauricio
author_facet	Cabrera C.,María Elena Puga L.,Bárbara Torres,Vivianne Salinas,Mauricio
author_sort	Cabrera C.,María Elena
title	Evaluación del tratamiento de linfoma de Hodgkin con esquema ABVD en Chile
title_short	Evaluación del tratamiento de linfoma de Hodgkin con esquema ABVD en Chile
title_full	Evaluación del tratamiento de linfoma de Hodgkin con esquema ABVD en Chile
title_fullStr	Evaluación del tratamiento de linfoma de Hodgkin con esquema ABVD en Chile
title_full_unstemmed	Evaluación del tratamiento de linfoma de Hodgkin con esquema ABVD en Chile
title_sort	evaluación del tratamiento de linfoma de hodgkin con esquema abvd en chile
publisher	Sociedad Médica de Santiago
publishDate	2019
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872019000400437
work_keys_str_mv	AT cabreracmariaelena evaluaciondeltratamientodelinfomadehodgkinconesquemaabvdenchile AT pugalbarbara evaluaciondeltratamientodelinfomadehodgkinconesquemaabvdenchile AT torresvivianne evaluaciondeltratamientodelinfomadehodgkinconesquemaabvdenchile AT salinasmauricio evaluaciondeltratamientodelinfomadehodgkinconesquemaabvdenchile
_version_	1718437056785416192

Evaluación del tratamiento de linfoma de Hodgkin con esquema ABVD en Chile

Ejemplares similares